Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing JOTROL™, a patented resveratrol-based platform aimed at addressing neuroinflammation and promoting healthy aging [3] - The company is pursuing a dual-path strategy that includes a therapeutic pipeline for central nervous system (CNS) disorders and rare diseases, as well as a consumer longevity market through its Nugevia product line [3] - JOTROL™ has shown significantly improved bioavailability, enhancing its therapeutic potential [3] Upcoming Event - Jupiter Neurosciences will participate in the DealFlow Discovery Conference on January 28-29, 2026, where the Chairman and CEO, Christer Rosén, will present the company and hold one-on-one investor meetings [1][2] - Investors can attend the conference at no cost and are encouraged to schedule meetings with the management team [2] Product Pipeline - The company's prescription pipeline is currently focused on CNS disorders, with a Phase IIa clinical trial ongoing for Parkinson's disease, and includes indications for Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS [3] - Nugevia, the consumer product line, aims to bring clinical-grade science to the supplement market, supporting mental clarity, skin health, and mitochondrial function [3]